COYA Stock Forecast & Price Target

Coya Therapeutics is attractive because its lead asset COYA 302 is built on a biologically compelling Treg-restoration strategy that has shown positive preclinical and clinical signals, including improved Treg health, reduced inflammation, and early efficacy in ALS and FTD. The investment case is further strengthened by Fast Track Designation in ALS, active ALSTARS enrollment across about 25 sites, and a cash position of $43.2M at June 30 that management says supports runway into 2H27, reducing near-term financing pressure. Although ALSTARS still carries high clinical risk, the company’s disciplined execution, broad platform potential across ALS and FTD, and encouraging safety profile support a favorable fundamental outlook.

Coya Therapeutics is a clinical-stage biotech with no revenue-generating products, so its valuation depends almost entirely on unproven pipeline success rather than current commercial cash flow. The company faces major clinical and regulatory uncertainty across phase I/II/III studies, and any failure to achieve clinically meaningful efficacy, obtain FDA or EMA approval, or secure regulatory alignment could sharply reduce the prospects of its Treg-based therapies. Meanwhile, continuing cash burn, likely need for additional debt or equity financing, potential dilution, and intense competition from better-resourced rivals create a fragile fundamental profile with limited margin of safety.